Terns Pharmaceuticals, Inc. (TERN) has a negative trailing P/E of -51.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -1.96%.
Criteria proven by this page:
Overall SharesGrow Score: 45/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -24.9 | 0.00 | 6.10 | 0.00 | - |
| 2019 | -6.7 | -0.02 | 109.70 | 0.00 | - |
| 2020 | -15.7 | 0.38 | 6.74 | 0.00 | - |
| 2021 | -3.6 | -0.15 | 1.11 | 178.65 | - |
| 2022 | -6.1 | 0.39 | 1.32 | 0.00 | - |
| 2023 | -5.1 | 0.21 | 1.81 | 0.00 | - |
| 2024 | -5.0 | 0.42 | 1.27 | 0.00 | - |
| 2025 | -39.1 | 4.87 | 3.74 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.74 | $0.00 | $-17.71M | - |
| 2019 | $-2.74 | $0.00 | $-68.82M | - |
| 2020 | $-1.61 | $0.00 | $-40.57M | - |
| 2021 | $-1.98 | $1M | $-50.16M | -5015.8% |
| 2022 | $-1.67 | $0.00 | $-60.35M | - |
| 2023 | $-1.27 | $0.00 | $-90.21M | - |
| 2024 | $-1.12 | $0.00 | $-88.85M | - |
| 2025 | $-1.03 | $0.00 | $-96.21M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.16 | $-1.41 – $-0.76 | $960K | $960K – $960K | 4 |
| 2027 | $-1.42 | $-1.60 – $-1.20 | $5.77M | $5.77M – $5.77M | 6 |
| 2028 | $-1.73 | $-2.24 – $-1.21 | $7.9M | $7.9M – $7.9M | 5 |
| 2029 | $-1.69 | $-1.69 – $-1.69 | $44.6M | $44.6M – $44.6M | 1 |
| 2030 | $-1.11 | $-1.11 – $-1.11 | $220.26M | $220.26M – $220.26M | 1 |
